Drug Profile
Research programme: retinol-binding protein 4 inhibitors - Isis Pharmaceuticals
Alternative Names: RBP4 antisenseLatest Information Update: 07 Apr 2011
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action RBP4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 09 Jun 2009 Preclinical trials in Type-2 diabetes mellitus in USA (Parenteral)